Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dna X (SONM) EBITDA (2018 - 2025)

Historic EBITDA for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to -$4.0 million.

  • Dna X's EBITDA fell 6750.84% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.2 million, marking a year-over-year decrease of 15153.24%. This contributed to the annual value of -$33.6 million for FY2024, which is 665730.99% down from last year.
  • As of Q3 2025, Dna X's EBITDA stood at -$4.0 million, which was down 6750.84% from -$6.7 million recorded in Q2 2025.
  • Over the past 5 years, Dna X's EBITDA peaked at $747000.0 during Q2 2023, and registered a low of -$22.1 million during Q4 2024.
  • Moreover, its 5-year median value for EBITDA was -$4.0 million (2025), whereas its average is -$5.0 million.
  • In the last 5 years, Dna X's EBITDA surged by 13566.61% in 2023 and then crashed by 166127.49% in 2024.
  • Dna X's EBITDA (Quarter) stood at -$11.7 million in 2021, then soared by 90.98% to -$1.1 million in 2022, then dropped by 18.51% to -$1.3 million in 2023, then tumbled by 1661.27% to -$22.1 million in 2024, then soared by 81.99% to -$4.0 million in 2025.
  • Its EBITDA was -$4.0 million in Q3 2025, compared to -$6.7 million in Q2 2025 and $645000.0 in Q1 2025.